$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Science / Discoveries

Non-Hallucinogenic LSD Analog Mirrors LSD Gene Signals

BetterLife Pharma announced on Tuesday, November 17, 2026 that researchers at Carleton University found BETR-001 changed gene expression in mouse brain cells in patterns that broadly overlapped with LSD. The study used single-nucleus RNA sequencing on cells from the prefrontal and cingulate cortex of adult male and female mice. BETR-001 is a non-hallucinogenic derivative of LSD, and these are animal results. No person has taken the compound in a trial.

TML Science DeskNov 17, 12:14 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

A fluorescence microscopy image of a mouse embryo cerebellum (archive). The Carleton University study measured gene activity in individual brain cell nuclei from mice treated with BETR-001 or LSD. Photo: NIH Image Gallery, via Wikimedia Commons.
Summary

BetterLife plans to file an Investigational New Drug application in the first quarter of 2027 and start clinical development that year. The mouse data decide whether that filing has a mechanism story behind it, and the first human study decides everything after that.

Tap a passage. React to the part that matters.

In a Carleton University laboratory, researchers dosed adult mice with two compounds and then read the animals' brain cells one nucleus at a time. The results reached a conference poster in Washington, D.C. on Tuesday.

The compounds were LSD and BETR-001, the R:R stereoisomer of 2-Br-LSD, a derivative engineered to drop the hallucinogenic effect. The team used single-nucleus RNA sequencing on cells from the prefrontal and cingulate cortex, a method that records which genes are switched on inside each individual cell nucleus.

BETR-001 produced gene expression changes tied to neuroplasticity and stress hormone signaling that broadly overlapped with the changes LSD produced. Both compounds touched genes involved in synaptic scaffolding and dendritic spine remodeling, the physical rebuilding of connections between neurons. Both also left signatures linked to trafficking of TrkB, the receptor for BDNF, a protein neurons use to support that remodeling.

The response was substantial in both male and female mice. Many of the specific genes that moved differed by sex, particularly after BETR-001 treatment, which means a single dosing story for both sexes isn't supported by this dataset. Earlier mouse studies gave BETR-001 a non-hallucinogenic behavioral profile, and the company is developing it as a preventive treatment for chronic cluster headache and chronic migraine.

The limits of the study are plain. Gene expression overlap is not pain relief, and a mouse cortex is not a person with cluster headaches. The study measured molecular responses at the cellular level; it did not measure headache outcomes in any species, and BETR-001 has not been approved by any regulator or tested in a human.

BetterLife holds a granted United States composition of matter patent covering BETR-001. Chief Executive Officer Ahmad Doroudian said the findings support the scientific rationale for the program as the company prepares to advance it into clinical development in 2027.

The poster itself carries the study's full title: "Mapping the Molecular and Cellular Effects of Psychedelics and Non-Hallucinogenic Analogs Using Single-Nucleus RNA Sequencing." It was presented on Tuesday, November 17, 2026 at Neuroscience 2026, the annual meeting of the Society for Neuroscience. Conference posters are preliminary reports, not peer reviewed papers, and the dataset hasn't yet faced the scrutiny a journal submission would bring.

The company plans to file its Investigational New Drug application in the first quarter of 2027. That filing, and the first human safety study behind it, will show whether the gene signals in mouse brain cells translate into a drug a person can take.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.